OMT-28
Phase 2Small molecule
OMT-28 is one of 36 small molecule programs targeting Mitochondrial Disease. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
376 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Calquence
AstraZenecaPreclinical
Calan
VVal Adams
Preclinical
OMT-28
OOmeicos Therapeutics GmbH
Phase 2
Xylocaine
MMEDRx USA, Inc.
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Preclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Statin
Bristol-Myers SquibbPreclinical
Liquamar
OOrganon and Co
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Mitochondrial Disease1 trial
Atrial Fibrillation1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OMT-28. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- OOmeicos Therapeutics GmbH